TECH - バイオテクネ （Bio-Techne Corp） バイオテクネTECHのチャート
TECHの企業情報
| symbol | TECH |
|---|---|
| 会社名 | Bio-Techne Corp （バイオテクネ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 バイオ・テクネ（Bio-Techne Corp）（旧名：TECHNE Corporation）はバイオテクノロジー製品、血液学校正器及びコントロールの開発・生産・販売に従事する企業である。同社は完全子会社Research and Diagnostic Systems Inc.、Boston Biochem Inc及びBiosPacific Inc.を通して事業を展開している。同社はバイオテクノロジー事業及び血液学事業の2つの部門を通して運営する。バイオテクノロジー事業部門は世界中においてバイオテクノロジーの研究・診断製品を開発・製造・販売する。血液学事業は研究・開発システム血液学区分により構成され、世界中において血液学コントロール・校正器を開発・製造する。 バイオテクネは米国のバイオテクノロジ―製品メ―カ―。バイオテクノロジ―製品および臨床診断管理製品を開発、製造、販売する。バイオテクノロジ―部門はバイオテクノロジ―研究と診断製品の開発、製造、販売を手掛ける。診断管理製品部門は臨床市場向けにコントロ―ル試薬および測定器を提供。 bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide. |
| 本社所在地 | 614 McKinley Place N.E. Minneapolis MN 55413 USA |
| 代表者氏名 | Robert V. Baumgartner Robert V. Baumgartner |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 612-379-8854 |
| 設立年月日 | 1976年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 2000人 |
| url | www.bio-techne.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tech |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 222.61500 |
| 終値（lastsale） | 189.31 |
| 時価総額（marketcap） | 7148019040.25 |
| 時価総額 | 時価総額（百万ドル） 7118.567 |
| 売上高 | 売上高（百万ドル） 642.99300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7275.813 |
| 当期純利益 | 当期純利益（百万ドル） 92.94900 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 BIO-TECHNE Corp revenues increased 14% to $643M. Net income before extraordinary items increased 22% to $93M. Revenues reflect Biotechnology segment increase of 16% to $421.5M Protein Platforms segment increase of 22% to $111.9M Diagnostics segment increase of 3% to $110.1M United States segment increase of 11% to $346.3M Europe_Middle East segment increase of 19% to $148.6M. |
TECHのテクニカル分析
TECHのニュース
American International Group Inc. Increases Stock Position in Bio-Techne Co. (NASDAQ:TECH) 2023/06/05 11:17:13 The AM Reporter
American International Group Inc. increased its position in shares of Bio-Techne Co. (NASDAQ:TECH – Get Rating) by 283.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 43,395 shares of the biotechnology company’s stock after buying an additional 32,089 shares during the period. American International […]
Bio-Techne Co. (NASDAQ:TECH) Stock Holdings Increased by Raymond James Financial Services Advisors Inc. 2023/06/05 10:39:50 The AM Reporter
Raymond James Financial Services Advisors Inc. lifted its stake in Bio-Techne Co. (NASDAQ:TECH – Get Rating) by 312.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,087 shares of the biotechnology company’s stock after purchasing an additional 3,096 shares during the quarter. […]
BIO-TECHNE TO PRESENT AT THE 2023 JEFFERIES HEALTHCARE CONFERENCE 2023/05/25 11:00:00 PR Newswire
MINNEAPOLIS, May 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023, at 12:30 p.m. EDT. A live webcast of…
Bio-Techne Corporation: Long-Term Quality, But At A Price 2023/05/18 22:42:08 Seeking Alpha
Bio-Techne Corporation has been a long term value creator, combining organic growth with sound M&A deals. Click here to read my analysis of TECH stock.
Thursday Is Your Last Chance To Buy Bio-Techne Before The Dividend Payout 2023/02/07 14:45:50 Benzinga
Thursday marks the last chance for investors to receive the next dividend payout from Bio-Techne (NASDAQ: TECH ). What''s Happening The company announced on Thursday that it would pay shareholders a quarterly dividend of 8 cents per share. On Friday, Bio-Techne will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will … Full story available on Benzinga.com
Bio-Techne Corp. PT Lowered to $100 at Craig-Hallum 2023/02/03 14:46:11 Investing.com
https://www.investing.com/news/pro/biotechne-corp-pt-lowered-to-100-at-craighallum-432SI-2995119
Bio-Techne Corporation (TECH) Q2 2023 Earnings Call Transcript 2023/02/02 16:51:02 Seeking Alpha
Bio-Techne Corporation (NASDAQ:NASDAQ:TECH) Q2 2023 Earnings Conference Call February 2, 2023 9:00 AM ETCompany ParticipantsDavid Clair - Vice President of Investor RelationsChuck Kummeth -…
Bio-Techne declares $0.08 dividend 2023/02/02 11:46:40 Seeking Alpha
Bio-Techne (NASDAQ:TECH) declares $0.08/share quarterly dividend, in-line with prior dividend of $0.32 (adjusting for 4 for 1 stock split).Forward yield 0.39%Payable Feb.
Bio-Techne GAAP EPS of $0.31 misses by $0.03, revenue of $271.58M misses by $18.15M 2023/02/02 11:36:07 Seeking Alpha
Bio-Techne press release (TECH): Q2 GAAP EPS of $0.31 misses by $0.03.Revenue of $271.58M (+0.9% Y/Y) misses by $18.15M.
Bio-techne Corp Common Stock TECH Trading Signals 2023/01/04 09:45:00 Stock Traders Daily
Buy and Sell Signals for Bio-techne Corp Common Stock TECH that help investors manage their investment in TECH
BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2022/12/21 12:00:00 PR Newswire
MINNEAPOLIS, Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 8:15 a.m. PST. A live webcast of…
Stem Cell Assay Global Market Report 2022: Ukraine-Russia War Impact 2022/12/12 11:33:00 GlobeNewswire
Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc. Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc.